nasdaq copenhagen velo industry pharmaceuticals headquarters h rsholm denmark key people william j. polvino m.d. president and ceo kim bj rnstrup chairman products orally delivered pharmaceuticals number of employees 30 website www.veloxis.com veloxis pharmaceuticals a s formerly lifecycle pharma a s develops improved versions of difficult to formulate drugs with its proprietary drug formulation technology called meltdose . veloxis is focused on building a clinical and market stage pharmaceutical business around its late stage transplant immunosuppression product candidate lcp tacro . the company was founded in 2002 as a spin off from h. lundbeck a s. veloxis is headquartered in horsholm denmark with an office in edison new jersey . 1 contents 1 meltdose technology platform 2 product pipeline 3 3 references 4 external links meltdose technology platform edit meltdose works by incorporating a drug substance with low water solubility into a meltable vehicle . 2 it is then sprayed on an inert particulate carrier using fluid bed equipment . the melt is solidified when deposed on a particle carrier and thus captures the active drug in a solid dispersion either as a solid solution or in a nano crystalline state . the particle size is then increased by controlling and optimizing the product temperature and feed rate of the melt . the granulate can be directly compressed into tablets without additional processing steps besides blending with a lubricant . in addition the technology allows for customization of the release profile . once in tablet form the dissolution profile and the particle size of drugs manufactured using meltdose technology remain stable allowing for a long shelf life . product pipeline 3 edit lcp tacro tacrolimus is a once daily dosage version of tacrolimus for prevention of rejection in organ transplant patients in two phase 3 clinical trials in kidney transplant patients . the first study in stable transplant patients showed that lcp tacro was non inferior in efficacy and safety compared to twice daily tacrolimus prograf esot ref . the second phase 3 clinical trial in de novo patients is ongoing . 4 a phase 3b clinical trial evaluating whether patients experiencing symptomatic tremor on twice daily tacrolimus demonstrate improvement in their tremors when switched to lcp tacro is ongoing . 5 fenoglide fenofibrate for dyslipidemia marketed in the u.s. by santarus inc. 6 references edit http www.veloxis.com van arnum p. formulation development forum controlled agglomeration for poorly soluble drugs . pharmaceutical technology 35 7 . http www.veloxis.com clinicaltrials.gov identifier nct01187953 clinicaltrials.gov identifier nct01438710 http www.santarus.com external links edit veloxis pharmaceuticals website retrieved from https en.wikipedia.org w index.php title veloxis pharmaceuticals & oldid 676725095 categories pharmaceutical companies of denmarklife science companies based in copenhagencompanies based in h rsholm municipalitycompanies established in 1999 navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page print export create a bookdownload as pdfprintable version languages add links this page was last modified on 18 august 2015 at 19 39 . text is available under the creative commons attribution sharealike license ; additional terms may apply . by using this site you agree to the terms of use and privacy policy . wikipedia is a registered trademark of the wikimedia foundation inc. a non profit organization . privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view